Location:Home > Project Description > ADA308

  Tarrex is co-developing ADA-308 with Aranda Pharma of Finland.  ADA-308 is a small molecule androgen receptor(AR) antagonist designed to combat advanced prostate cancer. The ADA-308program consists of 650+ designed chemical scaffolds, 220+ profiled moleculesand has a global IP protection in the key market areas.

  Prostate cancer is themost common cancer in men and the 2nd leading cause of cancer deathaffecting millions of men worldwide. Androgens are needed to thrive prostatecancer cells making androgen deprivation therapy (ADT) the backbone foradvanced prostate cancer treatment. ADT can be achieved by lowering androgenlevels either surgically or chemically, or blocking their action via androgenreceptor, AR, antagonists. While initially effective the response is often short-lived and disease progression occurs despite castrate levels of androgenshence the naming castration resistant prostate cancer, CRPC, for the mostadvanced form of the disease. At molecular level, progression to CRPC ischaracterized e.g. by increase in intra-tumoralandrogen production, aberrant AR expression including AR gene amplifications,AR mutations and/or ligand-independent AR splice variants leading to persistentAR activation. The realization that persistent activation of AR signalingpathway underlies the development of CRPC has led to the development of potentnext generation anti-androgens such as abiraterone and enzalutamide, which slowdown disease progression and prolong the survival of CRPC patients. However,some CRPC patients remain unresponsive even for these novel agents andtreatment resistance develops also in responsive ones over time underlining theneed for new treatment options.

  Aranda’s lead asset, ADA-308, is an AR antagonist that retains antagonism in treatment-resistantcells making it suitable drug candidate for patients that have undergonetreatment with 1st or 2nd generation AR antagonists. The program is in the late stage of preclinical development in the candidateselection phase. 

  For more information, please visit